JP2012510467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510467A5 JP2012510467A5 JP2011538209A JP2011538209A JP2012510467A5 JP 2012510467 A5 JP2012510467 A5 JP 2012510467A5 JP 2011538209 A JP2011538209 A JP 2011538209A JP 2011538209 A JP2011538209 A JP 2011538209A JP 2012510467 A5 JP2012510467 A5 JP 2012510467A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cyano
- amino
- substituent
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- GXLAKHKBZJXGHF-UHFFFAOYSA-N 2-chloro-n-[3-[[7-cyano-2-(cyclopropanecarbonylamino)-1,3-benzothiazol-6-yl]oxy]phenyl]-3-(2-cyanopropan-2-yl)benzamide Chemical compound N#CC(C)(C)C1=CC=CC(C(=O)NC=2C=C(OC=3C(=C4SC(NC(=O)C5CC5)=NC4=CC=3)C#N)C=CC=2)=C1Cl GXLAKHKBZJXGHF-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- LWHUINHGFIXZQT-UHFFFAOYSA-N n-[7-cyano-6-[3-[[2-[3-(trifluoromethyl)phenyl]acetyl]amino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)NC=2C=C(OC=3C(=C4SC(NC(=O)C5CC5)=NC4=CC=3)C#N)C=CC=2)=C1 LWHUINHGFIXZQT-UHFFFAOYSA-N 0.000 claims 2
- ZLKPQAVVJKWQEL-UHFFFAOYSA-N n-[7-cyano-6-[3-[[6-(trifluoromethyl)pyridin-3-yl]carbamoylamino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1NC(=O)NC1=CC=CC(OC=2C(=C3SC(NC(=O)C4CC4)=NC3=CC=2)C#N)=C1 ZLKPQAVVJKWQEL-UHFFFAOYSA-N 0.000 claims 2
- YMMZSUHTTYMCQY-UHFFFAOYSA-N n-[7-cyano-6-[4-fluoro-3-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-1,3-benzothiazol-2-yl]cyclopropanecarboxamide Chemical compound C1=C(NC(=O)NC=2C=CC(=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 YMMZSUHTTYMCQY-UHFFFAOYSA-N 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001555 benzenes Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 229940043274 prophylactic drug Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011538209A JP5640014B2 (ja) | 2008-12-02 | 2009-12-01 | 抗癌剤としてのベンゾチアゾール誘導体 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008307581 | 2008-12-02 | ||
| JP2008307581 | 2008-12-02 | ||
| JP2009125256 | 2009-05-25 | ||
| JP2009125256 | 2009-05-25 | ||
| JP2011538209A JP5640014B2 (ja) | 2008-12-02 | 2009-12-01 | 抗癌剤としてのベンゾチアゾール誘導体 |
| PCT/JP2009/070447 WO2010064722A1 (en) | 2008-12-02 | 2009-12-01 | Benzothiazole derivatives as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510467A JP2012510467A (ja) | 2012-05-10 |
| JP2012510467A5 true JP2012510467A5 (cg-RX-API-DMAC7.html) | 2013-01-10 |
| JP5640014B2 JP5640014B2 (ja) | 2014-12-10 |
Family
ID=42026212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538209A Expired - Fee Related JP5640014B2 (ja) | 2008-12-02 | 2009-12-01 | 抗癌剤としてのベンゾチアゾール誘導体 |
Country Status (40)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20090370A1 (es) * | 2007-06-05 | 2009-04-30 | Takeda Pharmaceutical | Derivados de heterociclo fusionado como inhibidores de quinasa |
| WO2009025358A1 (ja) * | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| WO2010064611A1 (ja) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
| CN104428001A (zh) * | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
| DK2888010T3 (da) | 2012-08-22 | 2021-06-28 | Univ Cornell | Fremgangsmåder til at hæmme fascin |
| US9670203B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| CN103435572B (zh) * | 2013-07-16 | 2015-02-04 | 浙江医药高等专科学校 | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 |
| CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
| CN103382190B (zh) * | 2013-07-16 | 2015-01-14 | 浙江医药高等专科学校 | 一类噻唑并环己烷类化合物、其制备方法和用途 |
| CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
| CN111349087B (zh) | 2014-02-20 | 2023-07-14 | 康奈尔大学 | 用于抑制肌成束蛋白的化合物和方法 |
| US11214836B2 (en) | 2014-07-15 | 2022-01-04 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
| US20190117652A1 (en) * | 2014-12-23 | 2019-04-25 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| CN109053630B (zh) * | 2018-08-22 | 2022-04-01 | 中国人民解放军第二军医大学 | 一种苯并噻唑类衍生物及其用途 |
| WO2020097398A1 (en) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020232445A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Modulators of pyrimidine nucleotide biosynthetic pathways |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CN112094248B (zh) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | 一种取代苯并噻唑类化合物及其用途 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| TW202325289A (zh) | 2021-11-09 | 2023-07-01 | 美商雅捷可斯治療公司 | Ｊａｋ２抑制劑之形式及組合物 |
| CN115724837B (zh) * | 2022-10-26 | 2024-07-23 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2399026A (en) | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
| US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| CN1167420C (zh) | 1997-09-26 | 2004-09-22 | 赞塔里斯有限公司 | 用于调制丝氨酸/苏氨酸蛋白激酶功能的氮杂苯并咪唑类化合物 |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| GT200000002A (es) * | 1999-01-13 | 2002-01-09 | Ureas difenilicias x - carboxyaril sustituidas como inhibidores raf kinase. | |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1153920B1 (en) | 1999-01-22 | 2003-10-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives |
| WO2001002359A1 (en) | 1999-07-01 | 2001-01-11 | Ajinomoto Co., Inc. | Heterocyclic compounds and medicinal use thereof |
| DE60029007T2 (de) | 1999-11-05 | 2007-01-11 | Astrazeneca Ab | Quinazolin-derivate als vegf-hemmer |
| KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US7235658B2 (en) | 2000-03-06 | 2007-06-26 | Smithkline Beecham P.L.C. | Imidazol derivatives as Raf kinase inhibitors |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| ATE385794T1 (de) | 2000-06-21 | 2008-03-15 | Hoffmann La Roche | Benzothiazolderivate zur behandlung von alzheimer und parkinson |
| IL154949A0 (en) | 2000-09-21 | 2003-10-31 | Smithkline Beecham Plc | Imidazole derivatives as raf kinase inhibitors |
| MX242553B (es) | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| WO2002044156A2 (en) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| ES2309207T3 (es) | 2001-09-05 | 2008-12-16 | Smithkline Beecham Plc | Derivados furanicos sustituidos con piridina como inhibidores de quinasa raf. |
| GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| JP2005504793A (ja) | 2001-09-05 | 2005-02-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｒａｆキナーゼ阻害剤としてのヘテロサイクルカルボキサミド誘導体 |
| ES2290479T3 (es) | 2002-03-01 | 2008-02-16 | Smithkline Beecham Corporation | Diamino-pirimidinas y su uso como inhibidores de la angiogenesis. |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| NZ535985A (en) * | 2002-03-29 | 2007-04-27 | Chiron Corp | Substituted benzazoles and use thereof as RAF kinase inhibitors |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| US7378233B2 (en) | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
| DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| PL1682126T3 (pl) | 2003-10-16 | 2009-12-31 | Novartis Vaccines & Diagnostics Inc | Podstawione benzazole i ich zastosowanie jako inhibitorów kinazy Raf |
| WO2005112932A2 (en) | 2004-05-07 | 2005-12-01 | Exelixis, Inc. | Raf modulators and methods of use |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006071035A1 (en) | 2004-12-31 | 2006-07-06 | Lg Life Sciences, Ltd. | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives |
| WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
| CA2593803A1 (en) * | 2005-01-26 | 2006-08-03 | Irm Llc | Thiazole-amide compounds and compsitions as protein kinase inhibitors |
| BRPI0613451A2 (pt) | 2005-07-11 | 2011-01-11 | Mitsubishi Tanabe Pharma Corp | ativador de glicocinase, derivado de oxima, método para a preparação do referido derivado de oxima e uso |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| WO2007058482A1 (en) | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
| PT2010528T (pt) | 2006-04-19 | 2017-12-21 | Novartis Ag | Compostos benzotiazole e benzoxazole 6-o-substituídos e métodos de inibição da sinalização csf-1r |
| JPWO2008016131A1 (ja) | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| WO2008016192A2 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
| CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
| EP2157971B1 (en) | 2007-04-13 | 2012-01-11 | Rikshospitalet- Radiumhospitalet HF | Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
| EP2639316A1 (en) | 2007-05-11 | 2013-09-18 | The Johns Hopkins University | Biomarkers for melanoma |
| EP2150252A1 (en) | 2007-05-23 | 2010-02-10 | Novartis Ag | Raf inhibitors for the treatment of thyroid cancer |
| PE20090370A1 (es) | 2007-06-05 | 2009-04-30 | Takeda Pharmaceutical | Derivados de heterociclo fusionado como inhibidores de quinasa |
| JP2008307581A (ja) | 2007-06-15 | 2008-12-25 | Sanyo Special Steel Co Ltd | 管材の洗浄装置 |
| WO2009025358A1 (ja) | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| WO2009028629A1 (ja) | 2007-08-29 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| JP2009125256A (ja) | 2007-11-22 | 2009-06-11 | Kandado:Kk | 安眠枕 |
| CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
| US20110081362A1 (en) | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US20090275546A1 (en) | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
| US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2009
- 2009-11-25 JO JOP/2009/0448A patent/JO3101B1/ar active
- 2009-12-01 WO PCT/JP2009/070447 patent/WO2010064722A1/en not_active Ceased
- 2009-12-01 KR KR1020117015343A patent/KR101639092B1/ko not_active Expired - Fee Related
- 2009-12-01 EA EA201170735A patent/EA019447B1/ru not_active IP Right Cessation
- 2009-12-01 JP JP2011538209A patent/JP5640014B2/ja not_active Expired - Fee Related
- 2009-12-01 AU AU2009323274A patent/AU2009323274B2/en not_active Ceased
- 2009-12-01 BR BRPI0922109-3A patent/BRPI0922109A2/pt not_active IP Right Cessation
- 2009-12-01 NZ NZ593759A patent/NZ593759A/en not_active IP Right Cessation
- 2009-12-01 ES ES09775337.0T patent/ES2557304T3/es active Active
- 2009-12-01 ME MEP-2016-203A patent/ME02331B/me unknown
- 2009-12-01 CA CA2745144A patent/CA2745144C/en active Active
- 2009-12-01 GE GEAP200912278A patent/GEP20146003B/en unknown
- 2009-12-01 MX MX2011005836A patent/MX2011005836A/es active IP Right Grant
- 2009-12-01 MY MYPI20112494 patent/MY150989A/en unknown
- 2009-12-01 AR ARP090104620A patent/AR074435A1/es active IP Right Grant
- 2009-12-01 US US12/628,697 patent/US8143258B2/en not_active Expired - Fee Related
- 2009-12-01 SG SG2011038247A patent/SG171426A1/en unknown
- 2009-12-01 DK DK09775337.0T patent/DK2358689T5/en active
- 2009-12-01 SI SI200931334T patent/SI2358689T1/sl unknown
- 2009-12-01 EP EP09775337.0A patent/EP2358689B9/en active Active
- 2009-12-01 PL PL09775337T patent/PL2358689T3/pl unknown
- 2009-12-01 HU HUE09775337A patent/HUE026491T4/en unknown
- 2009-12-01 PE PE2011001128A patent/PE20110588A1/es active IP Right Grant
- 2009-12-01 UY UY0001032281A patent/UY32281A/es not_active Application Discontinuation
- 2009-12-01 HR HRP20151370TT patent/HRP20151370T1/hr unknown
- 2009-12-01 TW TW098140940A patent/TWI436987B/zh not_active IP Right Cessation
- 2009-12-01 RS RS20150768A patent/RS54370B9/sr unknown
- 2009-12-01 PT PT97753370T patent/PT2358689E/pt unknown
- 2009-12-01 CN CN200980155786.1A patent/CN102300854B/zh not_active Expired - Fee Related
-
2011
- 2011-05-26 IL IL213184A patent/IL213184A0/en active IP Right Grant
- 2011-05-30 TN TN2011000280A patent/TN2011000280A1/fr unknown
- 2011-06-01 DO DO2011000165A patent/DOP2011000165A/es unknown
- 2011-06-01 CL CL2011001299A patent/CL2011001299A1/es unknown
- 2011-06-23 ZA ZA2011/04659A patent/ZA201104659B/en unknown
- 2011-06-24 CR CR20110366A patent/CR20110366A/es unknown
- 2011-06-29 EC EC2011011165A patent/ECSP11011165A/es unknown
- 2011-06-30 CO CO11082152A patent/CO6400140A2/es active IP Right Grant
- 2011-06-30 MA MA33985A patent/MA32911B1/fr unknown
-
2012
- 2012-01-10 US US13/347,302 patent/US8497274B2/en not_active Expired - Fee Related
-
2015
- 2015-12-15 SM SM201500316T patent/SMT201500316B/it unknown
- 2015-12-17 CY CY20151101155T patent/CY1117178T1/el unknown